A number of research firms have changed their ratings and price targets for Core Laboratories N.V. (NYSE: CLB):

  • 10/11/2017 – Core Laboratories N.V. was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Core Laboratories boasts of a unique business model, disciplined financial management and technological expertise. We also like CLB's leadership position in the reservoir optimization niche, along with its global footprint and deep portfolio of proprietary products and services. CLB’s low asset intensive operations and limited capex needs allow it to generate substantial free cash flows and operate profitably even in this low commodity price environment. However, we are concerned of the company’s high leverage and paucity of deepwater drilling orders which might hamper the specialized service provider’s near-term results. Therefore, until the commodity price environment improves, we take a cautious stance on the prospects of the stock.”
  • 10/10/2017 – Core Laboratories N.V. is now covered by analysts at Deutsche Bank AG. They set a “buy” rating and a $109.00 price target on the stock.
  • 10/6/2017 – Core Laboratories N.V. was given a new $100.00 price target on by analysts at Cowen and Company. They now have a “hold” rating on the stock.
  • 9/26/2017 – Core Laboratories N.V. was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Core Laboratories is anticipated to face near-term headwinds. Weak commodity prices have prompted upstream firms to lower capital spending, which has resulted in lesser work for the likes of Core Laboratories. Since crude prices are expected to remain low well into 2017, cash flows could see a significant decline in the coming months. The paucity of deepwater drilling orders and lower levels of new wells, which will hamper the specialized service provider’s near-term results, are other negatives in the CLB story. Therefore, ahead of its third-quarter results, we see the company as a risky bet that is best avoided at the moment.”
  • 9/12/2017 – Core Laboratories N.V. was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Core Laboratories boasts of a unique business model, disciplined financial management and technological expertise. We also like CLB's leadership position in the reservoir optimization niche, along with its global footprint and deep portfolio of proprietary products and services. CLB’s low asset intensive operations and limited capex needs allow it to generate substantial free cash flows and operate profitably even in this low commodity price environment. However, we are concerned of the company’s high leverage and paucity of deepwater drilling orders which might hamper the specialized service provider’s near-term results. Therefore until the commodity price environment improves, we take a cautious stance on the prospects of the stock.”
  • 9/7/2017 – Core Laboratories N.V. had its price target lowered by analysts at Royal Bank Of Canada from $115.00 to $112.00. They now have an “outperform” rating on the stock.
  • 9/1/2017 – Core Laboratories N.V. had its “hold” rating reaffirmed by analysts at Cowen and Company. They now have a $100.00 price target on the stock.
  • 9/1/2017 – Core Laboratories N.V. was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 9/1/2017 – Core Laboratories N.V. had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $115.00 price target on the stock.
  • 8/24/2017 – Core Laboratories N.V. was upgraded by analysts at Credit Suisse Group from a “neutral” rating to an “outperform” rating. They now have a $110.00 price target on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 8/14/2017 – Core Laboratories N.V. was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.

Core Laboratories N.V. (CLB) opened at 96.57 on Thursday. The firm has a market cap of $4.26 billion, a PE ratio of 59.25 and a beta of 1.64. The stock has a 50 day moving average of $94.14 and a 200 day moving average of $102.43. Core Laboratories N.V. has a 12-month low of $86.55 and a 12-month high of $125.83.

Core Laboratories N.V. (NYSE:CLB) last released its quarterly earnings data on Monday, July 24th. The oil and gas company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.01. The company had revenue of $163.90 million during the quarter, compared to analyst estimates of $168.23 million. Core Laboratories N.V. had a net margin of 11.80% and a return on equity of 49.29%. Core Laboratories N.V.’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.35 EPS. On average, equities research analysts anticipate that Core Laboratories N.V. will post $1.98 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, November 21st. Shareholders of record on Friday, October 20th will be paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 2.28%. Core Laboratories N.V.’s dividend payout ratio (DPR) is presently 134.15%.

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Receive News & Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related companies with MarketBeat.com's FREE daily email newsletter.